drugset / Trial / NCT03833206
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
Timeline
- Start
- 2027-01-15
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PDC-1421 | Unknown | 1 unknown | Oral |
| Subject | PDC-1421 | Unknown | 2 unknown | Oral |